|
|
|
|
 |
Supplying to customers in these markets puts your company on the world map of the |
|
|
pharmaceutical industry, gives you an edge over your competitors, adds prestige, and carries |
|
|
weight in any part of the world. |
|
|
|
|
 |
Penetrating these high entry-barrier markets means lesser competition, better price |
|
|
realizations, and long-term profits. |
|
|
|
|
 |
cGMP Audits and Rectification of Deficiencies in Manufacturing Facilities, Operations, Quality |
|
|
Systems, and Documentation. |
|
|
|
|
 |
Complete guidance on ICH Q7 / US FDA / EU / TPD cGMP Compliance |
|
|
|
|
 |
Arranging Validation and Analytical Support Services |
|
|
|
|
 |
Preparation of DMFs / Review of DMFs prepared by your staff before filing |
|
|
|
|
 |
Preparation of Quality Overall Summary / EU Expert Report |
|
|
|
|
 |
Appointment of Regulatory Agent(s) |
|
|
|
|
 |
Submission of DMF / EDMF |
|
|
|
|
 |
Sponsor Identification |
|
|
|
|
 |
Letters of Authorization / Access |
|
|
|
|
 |
Liaison with US FDA / TPD / EU Authorities / Regulatory Agent(s) |
|
|
|
|
 |
Pre-inspection cGMP Audits |
|
|
|
|
 |
Response to Deficiency Letters |
|
|
|
|
 |
Annual Reports (USA), Major / Minor Revisions and Updates |
|
|
|
|
 |
Knowledge of existing regulations and procedures, as well as future policy shifts. |
|
|
|
|
 |
Insight into how regulatory agencies think and what data they will need to approve |
|
|
specific products. |
|
|
|
|
 |
Extensive experience in interacting with regulatory agencies in the USA, Europe, and Canada. |